- Home
- CING
CING
Cingulate Inc.
as 12-18-2024 2:33pm EST
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | KANSAS CITY |
| Market Cap: | 13.5M | IPO Year: | 2021 |
| Target Price: | $96.00 | AVG Volume (30 days): | 91.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -22.31 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.80 - $152.40 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Cingulate Inc. News
CING Breaking Stock News: Dive into CING Ticker-Specific Updates for Smart Investing
Zacks Small Cap Research
a month ago
CING: Third Quarter Results
GlobeNewswire
a month ago
Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market
GlobeNewswire
2 months ago
Cingulate’s Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show
GlobeNewswire
3 months ago
Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301
GlobeNewswire
4 months ago
Cingulate to Participate in Benzinga All Live Access Event
Zacks Small Cap Research
4 months ago
CING: Initiating Coverage – Precision Timed Release Delivers Active-Day Coverage
Zacks Small Cap Research
4 months ago
CING: Initiating Coverage – Precision Timed Release Delivers Active-Day Coverage
GlobeNewswire
4 months ago
Cingulate Announces Adjournment of Special Meeting
Compare CING vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CING Cingulate Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.